Skip to main content

Home/ Vitamin D/ Group items tagged PCa

Rss Feed Group items tagged

Matti Narkia

Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk - Scien... - 1 views

  •  
    Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk.
    Yin L, Raum E, Haug U, Arndt V, Brenner H.
    Cancer Epidemiol. 2009 Dec;33(6):435-45. Epub 2009 Nov 25.
    PMID: 19939760
    doi:10.1016/j.canep.2009.10.014

    CONCLUSIONS: According to available evidence from longitudinal studies, serum 25(OH)D is not associated with PC incidence.
Matti Narkia

Vitamin D and prostate cancer - ScienceDirect - The Journal of Steroid Biochemistry and... - 0 views

  •  
    Vitamin D and prostate cancer.
    Tuohimaa P, Lyakhovich A, Aksenov N, Pennanen P, Syvälä H, Lou YR, Ahonen M, Hasan T, Pasanen P, Bläuer M, Manninen T, Miettinen S, Vilja P, Ylikomi T.
    J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):125-34.
    PMID: 11384870
    doi:10.1016/S0960-0760(00)00141-2
Matti Narkia

Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-α) in pr... - 0 views

  •  
    Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells.
    Golovko O, Nazarova N, Tuohimaa P.
    Life Sci. 2005 Jun 17;77(5):562-77. Epub 2005 Feb 25.
    PMID: 15904673
    doi:10.1016/j.lfs.2004.10.072

    Combined addition of human recombinant TNF-alpha with calcitriol or CB1093 cause enhanced effect in induction of apoptosis. We conclude that under physiological conditions vitamin D activates only the transcription of TNF-alpha gene, for TNF-alpha protein synthesis additional cofactors are required. Therefore a cooperation of vitamin D and TNF-alpha may play an important role in the control of cell growth in prostate cancer.
Matti Narkia

The role of Vitamin D3 metabolism in prostate cancer - ScienceDirect - The Journal of S... - 1 views

  •  
    The role of Vitamin D3 metabolism in prostate cancer.
    Lou YR, Qiao S, Talonpoika R, Syvälä H, Tuohimaa P.
    J Steroid Biochem Mol Biol. 2004 Nov;92(4):317-25. Epub 2004 Dec 19. Review.
    PMID: 15663995
    doi:10.1016/j.jsbmb.2004.10.007

    In summary, the local metabolism of hormonal Vitamin D seems to play an important role in the development and progression of prostate cancer.
Matti Narkia

Lack of Association between Serum Levels of 25-Hydroxyvitamin D and the Subsequent Risk... - 0 views

  •  
    Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men.
    Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA.
    Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2784-6.
    PMID: 18086789
    doi: 10.1158/1055-9965.EPI-07-0672
Matti Narkia

Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25... - 0 views

  •  
    Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk.
    Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E.
    Prostate. 2007 Jun 15;67(9):911-23.
    PMID: 17440943
    DOI: 10.1002/pros.20570

    RESULTS
    No association was found between these SNPs or their associated haplotypes and all PC subtypes except that haplotype 2 (A-f-b) with Cdx2 A, Fok1 f, and Bsm1 b alleles and haplotype 3 (A-F-B) with Cdx2 A, Fok1 F and Bsm1 B alleles compared to the most common haplotype (A-F-b), were associated with reduced risk of aggressive PC (high stage or Gleason sum 7; P = 0.02), both with two alleles suspected of being low risk. Carriers of the variant Cdx2 A allele who were deficient in plasma 25-hydroxyvitamin D (15 ng/ml) compared to non-carriers with normal 25-hydroxyvitamin D, had a lower risk of total and poorly differentiated PCs (Gleason sum 7) (P for interaction = 0.02 and 0.04, respectively). Plasma 1,25-dihydroxyvitamin D deficiency (26 pg/ml) was associated with a threefold risk of poorly differentiated PC (P for interaction = 0.01) when comparing carriers of the Cdx2 A allele to non-carriers with normal 1,25-dihydroxyvitamin D.

    CONCLUSION
    In this population of men, none of the VDR polymorphisms studied was associated with susceptibility to PC.

    Carriers of the variant Cdx2 A allele with low plasma 25-hydroxyvitamin D may experience a reduction in risk of total and poorly differentiated prostate cancers compared to non-carriers with adequate 25-hydroxyvitamin D.
Matti Narkia

Serum Vitamin D Concentration and Prostate Cancer Risk: A Nested Case-Control Study -- ... - 0 views

  •  
    Serum vitamin D concentration and prostate cancer risk: a nested case-control study.
    Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team.
    J Natl Cancer Inst. 2008 Jun 4;100(11):796-804. Epub 2008 May 27.
    PMID: 18505967
    doi:10.1093/jnci/djn152

    CONCLUSION: The findings of this large prospective study do not support the hypothesis that vitamin D is associated with decreased risk of prostate cancer; indeed, higher circulating 25(OH)D concentrations may be associated with increased risk of aggressive disease.

    In summary, results from this large prospective study of men who underwent standardized prostate cancer screening in the context of a screening trial do not support the hypothesis that higher serum vitamin D status is associated with decreased risk of prostate cancer. The study showed no association of vitamin D level with nonaggressive disease; however, it raises the possibility that higher vitamin D level may be associated with increased risks for aggressive disease, although a clear monotonic dose-response relationship was lacking. Along with recent reports of adverse associations for higher vitamin D status and risk of pancreatic (32) and esophageal (33,34) cancer, caution should be taken in recommending high doses of vitamin D or sunlight exposure to the general public for prostate cancer prevention. Future analyses are warranted to confirm these results and to further clarify the effects of vitamin D on aggressive prostate cancer.
Matti Narkia

Vitamin D Emerges as Treatment for Prostate Cancer - Cuts PSA Levels by Half - 0 views

  •  
    "(NaturalNews) Treatment with vitamin D supplements may slow the progress of , according to a study published in the journal BJU International.

    In the United States, prostate cancer is the second leading cause of cancer death among men, after lung cancer. Approximately 240,000 new cases are diagnosed every year, leading to 30,000 deaths.

    Researchers have suspected for nearly two decades that the so-called "sunshine vitamin" may play a role in the risk and progression of prostate cancer, but no studies have previously been conducted on its usefulness as a treatment."
Matti Narkia

Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within th... - 0 views

  •  
    Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjønneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larrañaga N, González CA, Argüelles MV, Sánchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ.
    Am J Epidemiol. 2009 May 15;169(10):1223-32. Epub 2009 Apr 9.
    PMID: 19359375

    In summary, the results of this large nested case-control study provide no evidence in support of a protective effect of circulating concentrations of vitamin D on the risk of prostate cancer.
Matti Narkia

The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of th... - 0 views

  •  
    The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature.
    Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J.
    Anticancer Res. 2009 Sep;29(9):3511-36. Review.
    PMID: 19667145

    CONCLUSION: Significant associations with VDR polymorphisms have been reported in cancer of the breast (Fok1, Bsm1, Taq1, Apa1, poly (A)), prostate (Fok1, Bsm1, Taq1, poly (A)), skin (Fok1, Bsm1, A-1210), colorectum (Fok1, Bsm1), ovary (Fok1, Apa1) and bladder (Fok1), and in renal cell carcinoma (Taq1, Apa1). However, conflicting data have been reported for most malignancies. After careful evaluation of the actual literature, it can be summarized that data indicating an association of VDR polymorphisms and cancer risk are strongest for breast cancer (Bsm1, Fok1), prostate cancer (Fok1) and malignant melanoma (MM) (Fok1). Data indicating an association of VDR polymorphisms and cancer prognosis are strongest for prostate cancer (Fok1), breast cancer (Bsm1, Taq1), MM (Bsm1) and renal cell carcinoma (Taq1).
Matti Narkia

A multicountry ecologic study of risk and risk reduction factors for prostate cancer mo... - 0 views

  •  
    A multicountry ecologic study of risk and risk reduction factors for prostate cancer mortality.
    Grant WB.
    Eur Urol. 2004 Mar;45(3):271-9.
    PMID: 15036670

    CONCLUSIONS: These results are consistent with insulin-like growth factor-I (IGF-I), being an important risk factor for prostate cancer, with alcohol and calcium being less important risk factors, and with allium family vegetables, and, to a lesser extent, vitamin D being important risk reduction factors. These results should provide guidance for additional studies on dietary and environmental links to prostate cancer.
Matti Narkia

Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). - Ca... - 0 views

  •  
    Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland).
    Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P.
    Cancer Causes Control. 2000 Oct;11(9):847-52.
    PMID: 11075874
    DOI: 10.1023/A:1008923802001

    CONCLUSIONS: We conclude that low levels of 25-VD associated with an increased risk for subsequent earlier exposure and more aggressive development of prostate cancer, especially before the andropause.
Matti Narkia

Calcidiol and prostate cancer - ScienceDirect - The Journal of Steroid Biochemistry and... - 0 views

  •  
    Calcidiol and prostate cancer.
    Tuohimaa P, Golovko O, Kalueff A, Nazarova N, Qiao S, Syvälä H, Talonpoika R, Lou YR.
    J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):183-90. Epub 2005 Jan 22. Review.
    PMID: 15860261
Matti Narkia

Vitamin D and the epidemiology of prostate cancer. - Semin Dial. 2005 Jul-Aug;18(4):276... - 0 views

  •  
    Vitamin D and the epidemiology of prostate cancer.
    Schwartz GG.
    Semin Dial. 2005 Jul-Aug;18(4):276-89. Review.
    PMID: 16076349
    DOI: 10.1111/j.1525-139X.2005.18403.x
Matti Narkia

Association between serum 25(OH)D and death from prostate cancer - British Journal of C... - 0 views

  •  
    Association between serum 25(OH)D and death from prostate cancer.
    Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE.
    Br J Cancer. 2009 Feb 10;100(3):450-4. Epub 2009 Jan 20.
    PMID: 19156140
    doi:10.1038/sj.bjc.6604865

    The serum level of 25(OH)D may be involved in disease progression and is a potential marker of prognosis in patients with prostate cancer.
Matti Narkia

Geographic variation of prostate cancer mortality rates in the United States: Implicati... - 0 views

  •  
    Geographic variation of prostate cancer mortality rates in the United States: Implications for prostate cancer risk related to vitamin D.
    Grant WB.
    Int J Cancer. 2004 Sep 1;111(3):470-1; author reply 472. No abstract available.
    PMID: 15221981
    10.1002/ijc.20220

    The implications of our results and those of Tuohimaa et al.[1] include the following. Vitamin D supplementation should be undertaken in wintertime, a period when it is impossible to produce vitamin D by solar UVB exposure in northeastern states.[13] Given these new results, the optimal vitamin D intake and production and serum 25(OH)-vitamin D3 levels for prostate cancer appear to be lower than for other cancers. However, when developing guidelines for vitamin D fortification, many factors should be included in the analysis, including all of the potential health benefits and possible risks of vitamin D, as well as age, sex, residence, child-bearing status, etc.[14] Also, the suggestion that daily vitamin D3 supplement doses of 100 g (4,000 IU)/day are safe[15] should be reexamined. Finally, in terms of preventing prostate cancer, more attention should be given to diet, which has the greatest environmental impact on risk of prostate cancer, with animal products being important risk factors and vegetable products, especially onions and other allium family members, being important risk-reduction factors.[16]
Matti Narkia

Vitamin D may help treat prostate cancer - 0 views

  •  
    The Toronto group gave a fixed low dose (2,000 units) of the prehormone, cholecalciferol, a very safe compound that never causes high calcium in the doses used. In fact, the lowest dose of cholecalciferol known to cause high blood calcium is more than 20,000 units. Therefore, the Toronto group got better results with one-tenth the comparable dose of deltanoids! Vieth wanted to use more cholecalciferol but widespread ignorance about the physiology and pharmacology of vitamin D remains and he could not get adequate dosing past the various review committees.
Matti Narkia

Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is sl... - 0 views

  •  
    Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer.
    Vieth R, Choo R, Deboer L, Danjoux C, Morton GC, Klotz L.
    Am J Ther. 2006 Sep-Oct;13(5):394-9.
    PMID: 16988533
    doi: 10.1097/01.mjt.0000174346.36307.02
Matti Narkia

Both high and low levels of blood vitamin D are associated with a higher prostate cance... - 0 views

  •  
    Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries.
    Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M.
    Int J Cancer. 2004 Jan 1;108(1):104-8.
    PMID: 14618623
    DOI: 10.1002/ijc.11375
Matti Narkia

Enzyme kinetics hypothesis to explain the U-shaped risk curve for prostate cancer vs. 2... - 0 views

  •  
    Enzyme kinetics hypothesis to explain the U-shaped risk curve for prostate cancer vs. 25-hydroxyvitamin D in nordic countries.
    Vieth R.
    Int J Cancer. 2004 Sep 1;111(3):468; author reply 469.
    PMID: 15221979
    DOI: 10.1002/ijc.20218
1 - 20 of 27 Next ›
Showing 20 items per page